Generation and Functional Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ
Overview
Authors
Affiliations
Cytokine gene delivery by viral vectors is a promising novel strategy for cancer immunotherapy. Semliki Forest virus (SFV) has many advantages as a delivery vector, including the ability to (i) induce p53-independent killing of tumor cells apoptosis, (ii) elicit a type-I interferon (IFN) response, and (iii) express high levels of the transgene. SFV vectors encoding cytokines such as interleukin (IL)-12 have shown promising therapeutic responses in experimental tumor models. Here, we developed two new recombinant SFV vectors encoding either murine tumor necrosis factor-α (TNF-α) or murine interferon-γ (IFN-γ), two cytokines with documented immunostimulatory and antitumor activity. The SFV vector showed high infection rate and cytotoxicity in mouse and human lung carcinoma cells . By contrast, mouse and human macrophages were resistant to infection with SFV. The recombinant SFV vectors directly inhibited mouse lung carcinoma cell growth , while exploiting the cancer cells for production of SFV vector-encoded cytokines. The functionality of SFV vector-derived TNF-α was confirmed through successful induction of cell death in TNF-α-sensitive fibroblasts in a concentration-dependent manner. SFV vector-derived IFN-γ activated macrophages toward a tumoricidal phenotype leading to suppressed Lewis lung carcinoma cell growth in a concentration-dependent manner. The ability of SFV to provide functional cytokines and infect tumor cells but not macrophages suggests that SFV may be very useful for cancer immunotherapy employing tumor-infiltrating macrophages.
Bacteria and RNA virus inactivation with a high-irradiance UV-A source.
Spunde K, Rudevica Z, Korotkaja K, Skudra A, Gudermanis R, Zajakina A Photochem Photobiol Sci. 2024; 23(10):1841-1856.
PMID: 39305443 DOI: 10.1007/s43630-024-00634-2.
Styrylpyridinium Derivatives for Fluorescent Cell Imaging.
Putralis R, Korotkaja K, Kaukulis M, Rudevica Z, Jansons J, Nilova O Pharmaceuticals (Basel). 2023; 16(9).
PMID: 37765053 PMC: 10535741. DOI: 10.3390/ph16091245.
Korotkaja K, Jansons J, Spunde K, Rudevica Z, Zajakina A Int J Mol Sci. 2023; 24(13).
PMID: 37445941 PMC: 10341749. DOI: 10.3390/ijms241310763.
Korotkaja K, Zajakina A Viruses. 2023; 15(5).
PMID: 37243145 PMC: 10221717. DOI: 10.3390/v15051060.
Spunde K, Korotkaja K, Zajakina A Biomedicines. 2022; 10(9).
PMID: 36140243 PMC: 9495732. DOI: 10.3390/biomedicines10092142.